Published in Expert Rev Vaccines on January 01, 2013
Comparative analysis of disease pathogenesis and molecular mechanisms of New World and Old World arenavirus infections. J Gen Virol (2013) 1.17
Inhibition of Innate Immune Responses Is Key to Pathogenesis by Arenaviruses. J Virol (2016) 1.06
Innate immune response to arenaviral infection: a focus on the highly pathogenic New World hemorrhagic arenaviruses. J Mol Biol (2013) 0.98
Human hemorrhagic Fever causing arenaviruses: molecular mechanisms contributing to virus virulence and disease pathogenesis. Pathogens (2015) 0.92
A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl Trop Dis (2015) 0.80
Characterization of the host response to pichinde virus infection in the Syrian golden hamster by species-specific kinome analysis. Mol Cell Proteomics (2015) 0.77
Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever. PLoS Pathog (2016) 0.77
Novel mechanism of arenavirus-induced liver pathology. PLoS One (2015) 0.77
Development of real-time reverse transcriptase qPCR assays for the detection of Punta Toro virus and Pichinde virus. Virol J (2016) 0.75
Toll-like receptor signalling. Nat Rev Immunol (2004) 34.74
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science (1998) 5.83
Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog (2009) 4.88
Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus. Am J Trop Med Hyg (1970) 4.29
MDA5/RIG-I and virus recognition. Curr Opin Immunol (2008) 4.05
Lassa fever. Curr Top Microbiol Immunol (2002) 3.01
Genetic diversity among Lassa virus strains. J Virol (2000) 3.00
Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol (2004) 2.99
Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles [corrected]. J Virol (2003) 2.87
Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol (2003) 2.75
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Imported lassa fever in Germany: molecular characterization of a new lassa virus strain. Emerg Infect Dis (2000) 2.69
CD8+ T cell cross-priming via transfer of proteasome substrates. Science (2004) 2.51
Marmoset models commonly used in biomedical research. Comp Med (2003) 2.50
New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res (2007) 2.47
Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J Infect Dis (1980) 2.38
Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts. Mol Phylogenet Evol (1997) 2.36
Risk maps of Lassa fever in West Africa. PLoS Negl Trop Dis (2009) 2.33
Biology and pathogenesis of lymphocytic choriomeningitis virus infection. Curr Top Microbiol Immunol (2002) 2.32
Pathologic and virologic study of fatal Lassa fever in man. Am J Pathol (1982) 2.14
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
Lassa fever: epidemiology, clinical features, and social consequences. BMJ (2003) 2.06
Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J Immunol (2004) 1.96
Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J Virol (2007) 1.95
A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J Virol (1993) 1.86
Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol (1987) 1.83
Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis. Bull World Health Organ (1975) 1.83
Effective vaccine for lassa fever. J Virol (2000) 1.74
Nucleotide sequence of the glycoprotein gene and intergenic region of the Lassa virus S genome RNA. Virology (1986) 1.69
Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol (2001) 1.66
Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-alpha gene expression. J Med Virol (1999) 1.65
Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation. J Clin Microbiol (2000) 1.63
Isolation of an arenavirus closely related to Lassa virus from Mastomys natalensis in south-east Africa. Bull World Health Organ (1977) 1.53
Pathogenesis of a pichinde virus strain adapted to produce lethal infections in guinea pigs. Infect Immun (1981) 1.51
Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antiviral Res (2007) 1.50
Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerg Infect Dis (2009) 1.50
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine (2009) 1.48
Pathogenesis of Lassa virus infection in guinea pigs. Infect Immun (1982) 1.47
Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J Virol (2009) 1.45
Completion of the Lassa fever virus sequence and identification of a RING finger open reading frame at the L RNA 5' End. Virology (1997) 1.44
A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol (2005) 1.42
Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J Virol (2007) 1.41
Detection of Lassa virus, Mali. Emerg Infect Dis (2010) 1.41
Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever. J Infect Dis (2001) 1.40
Nucleotide sequence of the S RNA of Lassa virus (Nigerian strain) and comparative analysis of arenavirus gene products. Virus Res (1991) 1.37
Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect Immun (1984) 1.36
Generation of reassortants between African arenaviruses. Virology (1992) 1.33
Novel arenavirus sequences in Hylomyscus sp. and Mus (Nannomys) setulosus from Côte d'Ivoire: implications for evolution of arenaviruses in Africa. PLoS One (2011) 1.32
Lassa virus hepatitis: a study of fatal Lassa fever in humans. Am J Trop Med Hyg (1986) 1.31
Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. J Virol (2004) 1.30
The Lassa fever virus L gene: nucleotide sequence, comparison, and precipitation of a predicted 250 kDa protein with monospecific antiserum. J Gen Virol (1997) 1.29
Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. Lancet (1987) 1.28
Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol (2010) 1.26
T cell-dependence of Lassa fever pathogenesis. PLoS Pathog (2010) 1.25
Old world arenaviruses enter the host cell via the multivesicular body and depend on the endosomal sorting complex required for transport. PLoS Pathog (2011) 1.25
Pathological and virological features of arenavirus disease in guinea pigs. Comparison of two Pichinde virus strains. Am J Pathol (1994) 1.25
Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J Virol (2000) 1.24
Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. J Virol (2011) 1.23
Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg (1985) 1.23
Genome-wide scans provide evidence for positive selection of genes implicated in Lassa fever. Philos Trans R Soc Lond B Biol Sci (2012) 1.23
Genetic identification of Kodoko virus, a novel arenavirus of the African pigmy mouse (Mus Nannomys minutoides) in West Africa. Virology (2007) 1.22
Pathogenesis of arenavirus hemorrhagic fevers. Expert Rev Anti Infect Ther (2011) 1.21
Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus. J Infect Dis (1982) 1.20
Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages. Microbes Infect (2006) 1.20
Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever. J Infect Dis (1987) 1.20
Mice lacking alpha/beta and gamma interferon receptors are susceptible to junin virus infection. J Virol (2010) 1.20
Establishing efficacy of human products using animals: the US food and drug administration's "animal rule". Vet Pathol (2010) 1.19
Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates. Trans R Soc Trop Med Hyg (1985) 1.17
Receptor binding and cell entry of Old World arenaviruses reveal novel aspects of virus-host interaction. Virology (2009) 1.16
Pathogenesis of Lassa fever in cynomolgus macaques. Virol J (2011) 1.16
Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity. J Gen Virol (2011) 1.15
Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virol J (2011) 1.13
Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection. Virus Res (1988) 1.11
Inhibition of the type I interferon antiviral response during arenavirus infection. Viruses (2010) 1.11
T cells in the central nervous system: the delicate balance between viral clearance and disease. J Infect Dis (2002) 1.10
Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies. Virology (2011) 1.10
Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. Virology (2004) 1.09
Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine (2008) 1.09
Lassa fever vaccine. Expert Rev Vaccines (2004) 1.08
Clinical observations in 42 patients with Lassa fever. Tropenmed Parasitol (1980) 1.08
Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J Virol (2006) 1.07
Simian hemorrhagic fever virus infection of rhesus macaques as a model of viral hemorrhagic fever: clinical characterization and risk factors for severe disease. Virology (2011) 1.07
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology (2006) 1.06
Amino acids from both N-terminal hydrophobic regions of the Lassa virus envelope glycoprotein GP-2 are critical for pH-dependent membrane fusion and infectivity. J Gen Virol (2007) 1.06
Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages. J Virol (2011) 1.06
Novel arenavirus, Zambia. Emerg Infect Dis (2011) 1.06
Junín virus infection activates the type I interferon pathway in a RIG-I-dependent manner. PLoS Negl Trop Dis (2012) 1.05
Functional interferon system is required for clearance of lassa virus. J Virol (2012) 1.05
Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology (2005) 1.03
Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus. J Virol (2011) 1.02
Pathology of Lassa virus infection in the rhesus monkey. Am J Trop Med Hyg (1982) 1.02
Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. Virol J (2010) 1.02
The fusion of artificial lipid membranes induced by the synthetic arenavirus 'fusion peptide'. Biochim Biophys Acta (1992) 1.02
Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin. J Med Virol (1983) 1.01
Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virus. J Med Virol (2002) 1.01
Molecular determinants of Pichinde virus infection of guinea pigs--a small animal model system for arenaviral hemorrhagic fevers. Ann N Y Acad Sci (2009) 0.97
Genomic and phylogenetic characterization of Merino Walk virus, a novel arenavirus isolated in South Africa. J Gen Virol (2010) 0.97